Welcome to our dedicated page for CERo Therapeutics news (Ticker: CERO), a resource for investors and traders seeking the latest updates and insights on CERo Therapeutics stock.
CERo Therapeutics Holdings, Inc. (CERO) is a clinical-stage biotechnology company developing chimeric engulfment receptor technology for cancer treatment. The company's research focuses on engineering immune cells to target and eliminate tumors through a mechanism distinct from conventional cell therapies. News coverage for CERo Therapeutics typically centers on clinical trial developments, regulatory milestones, and corporate financing activities characteristic of early-stage biotech companies.
This news feed tracks announcements related to CERo's lead compound CER-1236, which is being evaluated in Phase 1 clinical trials for hematologic malignancies and solid tumors. Key news categories include FDA regulatory updates such as IND clearances and clinical trial authorizations, clinical trial progress including site activations and enrollment updates, and intellectual property developments covering patent filings and approvals.
For investors and researchers following the immuno-oncology sector, CERo Therapeutics news provides insight into an emerging cell therapy platform. Coverage includes financing announcements and capital raises that fund ongoing research, partnership developments with clinical research organizations and medical institutions, and material corporate events disclosed through SEC filings. Note that CERo now trades on the OTC Markets following its transition from a major exchange, which may affect trading activity and news flow patterns.
Bookmark this page to follow developments from this clinical-stage oncology company as it advances through the drug development process.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in AML on January 7, 2026.
Key points: investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events to date; a patient with MDS that progressed to AML had a 61-day platelet transfusion–free interval, exceeding an 8-week benchmark; transfusion independence ended after a later round of lymphodepleting chemotherapy plus CER-1236. The company filed an amendment with the FDA to add advanced MDS and myelofibrosis cohorts and will host an analyst call on Jan 7, 2026 at 5:00 PM ET.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in acute myeloid leukemia (AML) on December 17, 2025. The company reported completion of the dose‑limiting toxicity (DLT) observation period for Cohort 1.
The first patient in Cohort 2 was dosed at 4e6 cells/kg (four times the Cohort 1 dose of 1e6 cells/kg) and completed the DLT observation period. A second patient in Cohort 1 received a fourth additional dose and remains on study. The trial is a first‑in‑human, multi‑center, open‑label Phase 1/1b study evaluating safety and preliminary efficacy with primary endpoints including AEs, SAEs, DLTs, ORR, CR, cCR, and MRD; PK is a secondary measure.
CERo Therapeutics (OTCQB: CERO) announced its shares will begin trading on the OTCQB market under ticker CERO effective December 2, 2025 at 8:00 AM ET.
No investor action is required. The company said it is evaluating additional up‑list options, including a potential listing on a major exchange to improve liquidity and investor accessibility. Management reiterated focus on advancing its Phase 1 trial of CER‑1236 for AML, noting the starting dosage in the current cohort was increased significantly versus the prior cohort.
CERo Therapeutics (OTC PINK: CERO) initiated the second cohort of its first-in-human Phase 1/1b trial of CER-1236 in acute myeloid leukemia on Nov 5, 2025. The first patient in cohort 2 received an initial dose equal to twice the cohort‑1 starting dose and a second identical dose 48 hours later. Investigators reported no dose‑limiting toxicities to date, supporting escalation. The open‑label, multi‑center study uses dose escalation to find a Phase 2 dose and an expansion phase to assess safety and preliminary efficacy with endpoints including AEs/SAEs, DLTs, ORR, CR, cCR, MRD and PK.
The company noted observed cell expansion and continues dosing while evaluating options to list the stock on a public exchange.
CERo Therapeutics (OTC PINK: CERO) will present preclinical data for lead compound CER-1236 in a poster at the Society for Immunotherapy of Cancer (SITC) conference, Nov 5–9, 2025, with the poster scheduled for Nov 8, 2025.
The poster, titled “CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion,” reports preclinical findings of sustained cell expansion across multiple antigen stimulations and a robust cytokine response, compared with CD3/CD28 polyclonal stimulation which induced strong initial activation but led to exhaustion.
The company noted these data align broadly with observations from its ongoing Phase 1/1b first-in-human study in AML/MDS populations; the trial is a two-part dose-escalation and expansion study assessing safety, tolerability, ORR/CR/cCR and MRD, with PK as a secondary measure.
CERo Therapeutics (OTC: CERO) confirmed its shares continue trading under the OTC PINK market, effective at market open on October 31, 2025, with no action required from investors.
The company said it is evaluating up-list options to improve liquidity and accessibility while maintaining full operations and staffing. CERo highlighted progress in its Phase 1 AML program for CER-1236, announcing initiation of Cohort 2 and an FDA-approved significant dosage increase for that cohort.
CERo Therapeutics (Nasdaq: CERO) announced that a Nasdaq Hearings Panel denied its request to continue listing, and Nasdaq trading will be suspended at the open on October 31, 2025. The Panel found the company noncompliant with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders’ equity, retroactive to April 22, 2025. The company previously reported regaining compliance after financings and asset transactions but later recorded a discounted sale of $5.0M marketable securities that prompted Nasdaq staff’s re‑determination.
CERo said it has received ~$2.25M from a Series E closing and subscriptions for ~$4.75M tied to conditions, is pursuing review by the Nasdaq Council, plans to seek trading on the OTC Markets, and intends to continue clinical trials including dosing of CER-1236, which showed early cell expansion and no observed toxicity in initial AML patients.
CERo Therapeutics (Nasdaq: CERO) reported investigators administered a third infusion of CER-1236 (1 million cells/kg) to a patient in Cohort One of its Phase 1 trial, completed about one week ago and matching the first two doses.
The third infusion precedes first dosing in Cohort Two, anticipated in coming weeks pending regulatory notifications. The company completed the first tranche (~$2.3 million) of a planned $7 million financing to extend cash runway and support Nasdaq compliance. The trial is ongoing; no CER-1236–attributable toxicities observed in the first three patients to date, and no safety or efficacy conclusions are being made yet.
CERo Therapeutics (Nasdaq: CERO) announced that CEO Chris Ehrlich will participate on a stem cell therapy panel titled “A Space That is Ready to Have its Day” at the Maxim Growth Summit on October 22, 2025 in New York City.
The Summit runs October 22–23, 2025 at the Hard Rock Hotel; the panel is scheduled for 1:30pm ET on October 22. A live webcast will be available on the company’s investor relations site, and a replay will be archived for 90 days. Mr. Ehrlich will be available for one-on-one meetings during the conference.
CERo Therapeutics (Nasdaq: CERO) announced on October 13, 2025 that it completed Cohort 1 of its first-in-human Phase 1/1b study of CER-1236 in acute myeloid leukemia (AML).
The company reported in-vivo cell expansion consistent with preclinical expectations and no dose-limiting toxicities (DLTs) in Cohort 1. The Dose Escalation Safety Committee approved initiation of Cohort 2, where three new patients will receive an increased starting dose pending regulatory approval.
CERo plans an additional infusion for the second Cohort 1 subject to explore multiple-infusion dosing versus single higher doses and said it is not currently pursuing acquisitions or partnerships while dose finding continues.
FAQ
What is the current stock price of CERo Therapeutics (CERO)?
What is the market cap of CERo Therapeutics (CERO)?
